ArticleJournal of neurology2019
Continuous subcutaneous apomorphine in advanced Parkinson's disease patients treated with deep brain stimulation.
Article in Journal of neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.
- Invasive therapies for Parkinson's disease: an adapted excerpt from the guidelines of the German Society of Neurology.Journal of neurology · 2025Pooled it
- Continuous Subcutaneous Infusion Delivery of Apomorphine in Parkinson's Disease: A Systematic Review.Movement disorders clinical practice · 2023Pooled it
- Continuous Subcutaneous Apomorphine as a Temporary Bridging Therapy for Dopamine Dysregulation Syndrome in Patients with Deep Brain Stimulation.Movement disorders clinical practice · 2026Article
- Continuous infusion therapy after deep brain stimulation in Parkinson's disease: indications, outcomes, and patient selection.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- What's in a name? reframing advanced Parkinson's disease as a multidimensional state.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Device aided therapies in Parkinson disease: an expert view on apomorphine.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Review
- Advanced therapies in Parkinson's disease: an individualized approach to their indication.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
- Nationwide Retrospective Analysis of Combinations of Advanced Therapies in Patients With Parkinson Disease.Neurology · 2023Article
- Access to device-aided therapies in advanced Parkinson's disease: navigating clinician biases, patient preference, and prognostic uncertainty.Journal of neural transmission (Vienna, Austria : 1996) · 2023Review
- Why do 'OFF' periods still occur during continuous drug delivery in Parkinson's disease?Translational neurodegeneration · 2022Review
- Parkinson's Disease Symptoms Associated with Developing On-State Axial Symptoms Early after Subthalamic Deep Brain Stimulation.Diagnostics (Basel, Switzerland) · 2022Article
- Continuous subcutaneous apomorphine infusion in the early phase of advanced Parkinson's disease: A prospective study of 22 patients.Clinical parkinsonism & related disorders · 2022Article
- Continuous Subcutaneous Apomorphine Infusion before Subthalamic Deep Brain Stimulation: A Prospective, Comparative Study in 20 Patients.Movement disorders clinical practice · 2021Article
- Continuous Subcutaneous Apomorphine Infusion in Advanced Parkinson's Disease: A Systematic Review.Cureus · 2021Review
- Personalised Advanced Therapies in Parkinson's Disease: The Role of Non-Motor Symptoms Profile.Journal of personalized medicine · 2021Article
- Combining Device-Aided Therapies in Parkinson's Disease: A Case Series and a Literature Review.Movement disorders clinical practice · 2021Review
- Infusion Therapies for Parkinson's Disease.Current neurology and neuroscience reports · 2020Review
- The Choice Between Advanced Therapies for Parkinson's Disease Patients: Why, What, and When?Journal of Parkinson's disease · 2020Review
- Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations.CNS drugs · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDeep brain stimulation (DBS) is an effective therapy for patients with advanced Parkinson's disease (PD). However, sometimes, it is not sufficient to adequately control motor symptoms. We describe our experience with continuous subcutaneous apomorphine infusion (APO) in patients with DBS.
methodsWe undertook a retrospective analysis of all patients treated with DBS and APO at our centre over 12 years. Subjects were allocated to four groups: (1) APO temporarily before DBS, (2) APO after DBS complications before a new DBS, (3) APO after definitive DBS removal, and (4) APO in patients with DBS and declining response. Motor state and other parameters were analysed and compared for the different treatments.
resultsData for 71 patients were evaluated. Group 1: (n = 18) patients improved their motor function significantly with both APO and DBS (off-hours before APO 5.4 ± 1.4; after APO 1.4 ± 1.2, p > 0.001; after DBS 0.7 ± 0.8, p < 0.001). Group 2: (n = 11) patients were found to have mild but significant worsening of motor state between the first DBS treatment (off-hours 0.7 ± 1.0) and APO (2.2 ± 1.5, p = 0.02), and improvement between APO and the second DBS treatment (off-hours 0.6 ± 0.8, p = 0.03). Group 3: (n = 12) patients had mild but significant worsening of motor function between DBS (off-hours 1.1 ± 1.0) and APO (2.0 ± 0.9, p = 0.03). Group 4: (n = 13) significant improvement in motor function was observed between DBS alone (off-hours 3.9 ± 2.6) and DBS combined with APO (2.2 ± 1.3, p = 0.03).
conclusionIn advanced PD, DBS may be not sufficient or may fail to control motor symptoms adequately. In these cases, APO, whether alone or in combination with DBS, is a good choice to improve the disease control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.